口服拓扑替康作为卵巢癌的二线治疗耐受性良好

{"title":"口服拓扑替康作为卵巢癌的二线治疗耐受性良好","authors":"Howard Hochster (Dr, Associate Professor of Medical Oncology and Clinical Pharmacology)","doi":"10.1054/ebon.2002.0026","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":100515,"journal":{"name":"Evidence-based Oncology","volume":"3 3","pages":"Pages 120-122"},"PeriodicalIF":0.0000,"publicationDate":"2002-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1054/ebon.2002.0026","citationCount":"0","resultStr":"{\"title\":\"Oral topotecan is well tolerated as second-line therapy for ovarian cancer\",\"authors\":\"Howard Hochster (Dr, Associate Professor of Medical Oncology and Clinical Pharmacology)\",\"doi\":\"10.1054/ebon.2002.0026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":100515,\"journal\":{\"name\":\"Evidence-based Oncology\",\"volume\":\"3 3\",\"pages\":\"Pages 120-122\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2002-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1054/ebon.2002.0026\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Evidence-based Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1363405402900267\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1363405402900267","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}